ArticleJournal of neurology2017
High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Mapping Cognitive Oncology: A Decade of Trends and Research Fronts.Medical sciences (Basel, Switzerland) · 2025Review
- Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.Nature communications · 2025Article
- Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke.Molecular psychiatry · 2025Article
- Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer.Frontiers in immunology · 2025Article
- Novel cerebrospinal fluid anti-central nervous system IgG antibodies can identify immunotherapy-responsive neuropsychiatric disorders.Frontiers in immunology · 2025Article
- Antibodies in neurological diseases: Established, emerging, explorative.Immunological reviews · 2024Review
- Computerized cognitive training improves cognitive function in primary breast cancer survivors.NPJ breast cancer · 2024Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- Overview of Paraneoplastic Autoantibody-Mediated Cognitive Impairment and Behavioral Changes: A Narrative Review.Cureus · 2024Review
- Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke.Brain, behavior, & immunity - health · 2023Article
- Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.Frontiers in immunology · 2023Article
- Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B).Journal of neurology · 2022Article
- Chronic presence of blood circulating anti-NMDAR1 autoantibodies impairs cognitive function in mice.PloS one · 2021Article
- Paraneoplastic Neurological Syndromes: Study of Prevalence in a Province of the Lombardy Region, Italy.Journal of clinical medicine · 2020Article
- Cognitive impact of neuronal antibodies: encephalitis and beyond.Translational psychiatry · 2020Review
- Serum Systemic Autoantibodies in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.Frontiers in neurology · 2020Article
- Neuronal autoantibodies associated with cognitive impairment in melanoma patients.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
- The Role of Cannabis within an Emerging Perspective on Schizophrenia.Medicines (Basel, Switzerland) · 2018Article
- Autoantibodies against N-methyl-d-aspartate receptor 1 in health and disease.Current opinion in neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent discovery of neuronal cell-surface antibodies profoundly expanded the clinical spectrum of paraneoplastic neurological syndromes. Many of these syndromes are associated with impaired cognitive function, a clinical symptom that is of increasing concern in cancer patients. However, the frequency of these antibodies in cancer patients and their relation to clinical syndromes is currently unknown. Here, we investigated the prevalence of neuronal cell-surface antibodies and associated paraneoplastic neurological syndromes in 323 patients with different cancer types and in 105 controls. Cerebrospinal fluid and serum samples were analysed for a large panel of anti-neuronal antibodies and all patients were screened for cognitive deficits. Blood-brain barrier integrity was assessed using the age-normalized albumin cerebrospinal fluid/serum ratio. Anti-neuronal autoantibodies were observed in 24.5% of cancer patients (in contrast to 3.1% in neurological control patients without cancer and 2.5% in healthy controls) and were almost exclusively detected in serum. The majority of antibodies were directed against cell-surface antigens (75.9%), most frequently IgA/IgM isotypes targeting the N-methyl-D-aspartate (NMDA) receptor. Cognitive deficits and cerebellar syndromes were significantly more prevalent in antibody-positive in comparison with antibody-negative patients (21 vs. 7%, p = 2.7 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.